Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Mar 2017

Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K

Abstract excerpt

Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Glioblastoma

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prognosis

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 27655368
DOI: 10.1007/s12094-016-1547-4

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?PMID 27655368Read ↗

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentSemantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesSemantic proximity Read ↗

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.Semantic proximity Read ↗

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomideSemantic proximity Read ↗

PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.Semantic proximity Read ↗

Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on GlioblastomaSemantic proximity Read ↗

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma MultiformeSemantic proximity Read ↗

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read ↗

DNA Damage Response and Growth Factor Signaling Pathways in Gliomagenesis and Therapeutic ResistanceSemantic proximity Read ↗

Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent MannerSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.